Product Description | Deoxypodophyllotoxin (DPT), a derivative of podophyllotoxin, is a lignan with potent antimitotic, anti-inflammatory and antiviral properties isolated from Anthriscus sylvestris. Deoxypodophyllotoxin, targets the microtubule , has a major impact in oncology not only as anti-mitotics but also as potent inhibitors of angiogenesis. Deoxypodophyllotoxin induces cell autophagy and apoptosis . Deoxypodophyllotoxin evokes increase of intracellular Ca 2+ concentrations in DRG neurons . In Vitro Deoxypodophyllotoxin (25-75 nM; 6-48 hours) increases the percentage of early apoptotic cell population from 2.05 to 5.62 and 18.49% for 24 h and 48 h, respectively. Deoxypodophyllotoxin (25-75 nM; 6-48 hours) treats SGC-7901 cells arrested in G2/M phase in time- and dose- dependent manners. Deoxypodophyllotoxin (25-75 nM; 6-48 hours) results in a remarkably time- and dose-dependent decrease in Cdc2 and Cdc25C expression levels and increases cyclin B1 within 6h, decreases PARP, Bcl-2 and caspase-3 activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: SGC-7901 cells Concentration: 25, 50, 75 nM Incubation Time: 6, 12, 24, 48 hours Result: Induced apoptosis in SGC-7901 Cells. Cell Cycle AnalysisCell Line: SGC-7901 cells Concentration: 25, 50, 75 nM Incubation Time: 6, 12, 24, 48 hours Result: Induced G2/M cell cycle arrest in SGC-7901 Cells Western Blot AnalysisCell Line: SGC-7901 cells Concentration: 25, 50, 75 nM Incubation Time: 6, 12, 24, 48 hours Result: Altered the expression of cyclin B1, Cdc2,Cdc25C, p-PARP, Bcl-2 and p-caspase-3 proteins. In Vivo Deoxypodophyllotoxin (intravenously injected; 5, 10, and 20 mg/kg; 3 times a week; 28 days) suppresses the tumors in a dose-dependent manner, the growth of tumors is inhibited by 22.19%, 47.91% and 50.93% with DPT at 5, 10 and 20 mg/kg, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Xenograft model of gastric cancer in nude mice with SGC-7901 cells Dosage: 5, 10, and 20 mg/kg Administration: Intravenously injected; 5, 10, and 20 mg/kg; 3 times a week; 28 days Result: Inhibited the growth of gastric cancer tumors. |
---|